Retatrutide Cardiovascular Risk Reduction Triumph-3 Trial

The retatrutide cardiovascular risk reduction triumph-3 trial (NCT05882045)[1] is a key Phase 3 study testing this triple hormone agonist in adults with obesity and established cardiovascular disease[1]. While topline results are not yet available and are expected in 2026, encouraging proxy data from the related TRIUMPH-4 trial show reductions in key CV risk markers like non-HDL cholesterol, triglycerides, hsCRP, and systolic blood pressure[2]. These findings highlight retatrutide's potential to address both weight loss and heart health in high-risk patients, positioning the retatrutide cardiovascular risk reduction triumph-3 trial as a cornerstone for future approvals.

Introduction to Retatrutide Cardiovascular Risk Reduction Triumph-3 Trial

Retatrutide, developed by Eli Lilly, stands out in obesity treatment research. This investigational drug targets multiple pathways to promote weight loss and improve metabolic health. The retatrutide cardiovascular risk reduction triumph-3 trial evaluates its specific benefits in patients facing heightened heart risks[1].

What Makes Retatrutide a Triple Hormone Agonist?

Retatrutide activates three key receptors: GIP, GLP-1, and glucagon.

• GIP helps regulate insulin and fat metabolism.
• GLP-1 slows